Published in Expert Rev Pharmacoecon Outcomes Res on October 01, 2013
Economic effects of clinical pharmacy interventions: a literature review. Am J Health Syst Pharm (2008) 3.11
The onecut transcription factor HNF6 is required for normal development of the biliary tract. Development (2002) 2.89
Endoscopic resection of ampullary lesions: a single-center 8-year retrospective cohort study of 91 patients with long-term follow-up. Surg Endosc (2013) 2.01
Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis (2012) 2.00
A comparative study of European rare disease and orphan drug markets. Health Policy (2010) 1.73
Impact, regulation and health policy implications of physician migration in OECD countries. Hum Resour Health (2004) 1.72
Congenital veno-venous malformations of the liver: widely variable clinical presentations. J Gastroenterol Hepatol (2007) 1.68
Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. J Med Econ (2010) 1.59
Generic and therapeutic substitution: ethics meets health economics. Int J Clin Pharm (2011) 1.45
Noncirrhotic presinusoidal portal hypertension is common in cystic fibrosis-associated liver disease. Hepatology (2011) 1.43
Increasing nurse staffing levels in Belgian cardiac surgery centres: a cost-effective patient safety intervention? J Adv Nurs (2010) 1.42
Paroxysmal exercise-induced dyskinesia and epilepsy is due to mutations in SLC2A1, encoding the glucose transporter GLUT1. Brain (2008) 1.41
Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol (2006) 1.32
Generic medicine pricing in Europe: current issues and future perspective. J Med Econ (2008) 1.32
Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe? Health Policy (2011) 1.29
Peripheral bile duct paucity and cholestasis in the liver of a patient with Alagille syndrome: further evidence supporting a lack of postnatal bile duct branching and elongation. Am J Surg Pathol (2005) 1.29
International trends in lifelong learning for pharmacists. Am J Pharm Educ (2007) 1.27
Prospective study comparing different indirect methods to measure portal pressure. J Vasc Interv Radiol (2011) 1.20
A comparative analysis of remuneration models for pharmaceutical professional services. Health Policy (2009) 1.18
Acute-on-chronic liver failure: current concepts on definition, pathogenesis, clinical manifestations and potential therapeutic interventions. Expert Rev Gastroenterol Hepatol (2011) 1.13
Drugs for rare diseases: influence of orphan designation status on price. Appl Health Econ Health Policy (2011) 1.10
The costs of breast cancer prior to and following diagnosis. Eur J Health Econ (2010) 1.09
Critical assessment of belgian reimbursement dossiers of orphan drugs. Pharmacoeconomics (2011) 1.09
Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries. Orphanet J Rare Dis (2013) 1.08
Personalizing health care: feasibility and future implications. BMC Med (2013) 1.07
The correlation between portal myofibroblasts and development of intrahepatic bile ducts and arterial branches in human liver. Liver (2002) 1.01
Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum. Appl Health Econ Health Policy (2013) 1.00
Neuroregulation of the neuroendocrine compartment of the liver. Anat Rec A Discov Mol Cell Evol Biol (2004) 0.99
Demand-side policies to encourage the use of generic medicines: an overview. Expert Rev Pharmacoecon Outcomes Res (2013) 0.97
The impact of reference-pricing systems in Europe: a literature review and case studies. Expert Rev Pharmacoecon Outcomes Res (2011) 0.97
Transcatheter arterial embolization for iatrogenic hemobilia is a safe and effective procedure: case series and review of the literature. Eur J Gastroenterol Hepatol (2012) 0.97
Does the market share of generic medicines influence the price level?: a European analysis. Pharmacoeconomics (2011) 0.96
Shining a light in the black box of orphan drug pricing. Orphanet J Rare Dis (2014) 0.96
Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol (2013) 0.95
Orphan drugs for rare diseases: is it time to revisit their special market access status? Drugs (2012) 0.95
Issues surrounding orphan disease and orphan drug policies in Europe. Appl Health Econ Health Policy (2010) 0.94
The impact of informing psychiatric patients about their medication: a systematic review. Pharm World Sci (2007) 0.94
Opposing expectations and suboptimal use of a local antibiotic hospital guideline: a qualitative study. J Antimicrob Chemother (2008) 0.93
Drug shortages in European countries: a trade-off between market attractiveness and cost containment? BMC Health Serv Res (2014) 0.93
Hepatitis B virus replication causes oxidative stress in HepAD38 liver cells. Mol Cell Biochem (2006) 0.92
Non-invasive liver elastography (Fibroscan) for detection of cystic fibrosis-associated liver disease. J Cyst Fibros (2009) 0.92
How can pharmacist remuneration systems in Europe contribute to generic medicine dispensing? Pharm Pract (Granada) (2012) 0.90
Clinical evidence for orphan medicinal products-a cause for concern? Orphanet J Rare Dis (2013) 0.90
Breast cancer resistance protein (BCRP/ABCG2) is expressed by progenitor cells/reactive ductules and hepatocytes and its expression pattern is influenced by disease etiology and species type: possible functional consequences. J Histochem Cytochem (2006) 0.89
Early versus late parenteral nutrition in ICU patients: cost analysis of the EPaNIC trial. Crit Care (2012) 0.89
Both Ca2+ -dependent and -independent pathways are involved in rat hepatic stellate cell contraction and intrahepatic hyperresponsiveness to methoxamine. Am J Physiol Gastrointest Liver Physiol (2006) 0.89
Barriers to the uptake of biosimilars and possible solutions: a Belgian case study. Pharmacoeconomics (2014) 0.88
Economic evaluations of homeopathy: a review. Eur J Health Econ (2013) 0.87
European drug shortages: a call for action! Int J Pharm Pract (2013) 0.87
Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. J Comp Eff Res (2014) 0.87
Generic medicines: solutions for a sustainable drug market? Appl Health Econ Health Policy (2013) 0.87
Hepatobiliary malignancies in Wilson disease. Liver Int (2014) 0.87
Clinicopathological features of focal nodular hyperplasia-like nodules in 130 cirrhotic explant livers. Am J Gastroenterol (2006) 0.86
Kiovig for primary immunodeficiency: reduced infusion and decreased costs per infusion. Int Immunopharmacol (2011) 0.86
Reimbursement of orphan drugs in Belgium: what (else) matters? Orphanet J Rare Dis (2014) 0.86
Length of stay after reaching clinical stability drives hospital costs associated with adult community-acquired pneumonia. Scand J Infect Dis (2012) 0.86
Market access of cancer drugs in European countries: improving resource allocation. Target Oncol (2013) 0.85
Giant liver hemangioma: the role of female sex hormones and treatment. Eur J Gastroenterol Hepatol (2011) 0.85
HBx or HCV core gene expression in HepG2 human liver cells results in a survival benefit against oxidative stress with possible implications for HCC development. Chem Biol Interact (2007) 0.84
A seven-gene set associated with chronic hypoxia of prognostic importance in hepatocellular carcinoma. Clin Cancer Res (2010) 0.84
Carbon monoxide produced by intrasinusoidally located haem-oxygenase-1 regulates the vascular tone in cirrhotic rat liver. Liver Int (2008) 0.84
Evaluating and improving orphan drug regulations in Europe: a Delphi policy study. Health Policy (2012) 0.84
Generic atypical antipsychotic drugs in Belgium: their influence and implications. J Comp Eff Res (2013) 0.84
Management dilemmas in pediatric nephrology: Cystinosis. Pediatr Nephrol (2015) 0.84
Treatment of non-alcoholic fatty liver disease: can we already face the epidemic? Acta Gastroenterol Belg (2013) 0.83
Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications. BMC Med (2014) 0.83
Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting. Pharmacoeconomics (2013) 0.82
[Orphan diseases and orphan medicines: a Belgian and European study]. J Pharm Belg (2009) 0.82
High-frequency vagus nerve stimulation improves portal hypertension in cirrhotic rats. Gut (2011) 0.82
HNF1B deficiency causes ciliary defects in human cholangiocytes. Hepatology (2012) 0.82
Ethical aspects of clinical research with minors. Eur J Pediatr (2012) 0.82
Valorising and creating access to innovative medicines in the European union. Front Pharmacol (2011) 0.81
Up-regulation of breast cancer resistance protein expression in hepatoblastoma following chemotherapy: A study in patients and in vitro. Hepatol Res (2008) 0.81
Uncertain diagnosis of fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-up. JIMD Rep (2014) 0.80
Two-tier approach for the detection of alpha-galactosidase A deficiency in kidney transplant recipients. Nephrol Dial Transplant (2008) 0.80
Defining the phenotype and diagnostic considerations in adults with congenital disorders of N-linked glycosylation. Expert Rev Mol Diagn (2014) 0.80
Societal value of generic medicines beyond cost-saving through reduced prices. Expert Rev Pharmacoecon Outcomes Res (2015) 0.79
Clinical, Biochemical, and Molecular Characterization of Novel Mutations in ABCA1 in Families with Tangier Disease. JIMD Rep (2014) 0.79
Body composition, volumetric and areal bone parameters in male-to-female transsexual persons. Bone (2008) 0.79
Misdiagnosis as asphyxiating thoracic dystrophy and CMV-associated haemophagocytic lymphohistiocytosis in Shwachman-Diamond syndrome. Eur J Pediatr (2013) 0.78
Cholestasis-induced pruritus treated with ultraviolet B phototherapy: an observational case series study. J Hepatol (2012) 0.78
Continuous versus on-demand pharmacotherapy of allergic rhinitis: evidence and practice. Respir Med (2010) 0.78
Histology obtained by needle biopsy gives additional information on the prognosis of hepatocellular carcinoma. Hepatol Res (2012) 0.78
A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium. Curr Med Res Opin (2008) 0.77
Implementing a hospital guideline on pneumonia: a semi-quantitative review. Int J Qual Health Care (2007) 0.77
Heterozygous α1-antitrypsin Z allele mutation in presumed healthy donor livers used for transplantation. Eur J Gastroenterol Hepatol (2013) 0.77
Analysis of Spanish generic medicines retail market: recommendations to enhance long-term sustainability. Expert Rev Pharmacoecon Outcomes Res (2014) 0.77
Evaluation of the interference by homogentisic acid and other organic acids on the enzymatic and Jaffé method creatinine assay. Clin Chem Lab Med (2012) 0.77
Development and validation of COMPASS: clinical evidence of orphan medicinal products - an assessment tool. Orphanet J Rare Dis (2013) 0.77
Lysosomal lipid vacuoles in macrophages located in the colon. J Inherit Metab Dis (2010) 0.77
Stimulating pharmaceutical innovation in the EU. Expert Rev Pharmacoecon Outcomes Res (2011) 0.76
The economic burden of COPD exacerbations. COPD (2010) 0.76
Comparative effectiveness research and measuring the level of pharmaceutical innovation in the EU. J Comp Eff Res (2012) 0.76